Jefferies Boosts Numbers on Questcor (QCOR) After Including Acthar DM/PM Sales in Model

Article Stock Quotes (1) Comments (0)

Jefferies lifted estimates and its price target on Buy-rated Questcor Pharmaceuticals (NASDAQ: QCOR) to $56.00 (from $52.00) after a call from the from the company clarifying its Acthar commercial strategy in rheumatology with initial focus on DM/PM following a peer-review publication of Acthar.

"Given a FDA-approved label, peer-reviewed data and a targeted mktg effort, we now include Acthar DM/PM sales in our valuation," the firm states.

FY12 EPS goes from $2.38 to $2.43 and FY13 EPS goes from $3.05 to $3.13.

For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.

Shares of Questcor Pharmaceuticals closed at $46.41 yesterday, with a 52 week range of $22.62-$48.98.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
• Goldman Sachs Upgrades Meritor (MTOR) to Buy
• Supernus (SUPN) PT Trimmed at Jefferies, But Survey Shows Significant Market Opportunity

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?